Biotechnology in Medicine: Driver of the Bioeconomy and a Vector for Export Growth

In the modern era, science has a direct impact on quality of life, sustainable development, and technological leadership. Science-intensive medical technologies are a key driver of the bioeconomy. The contemporary platform-based approach to healthcare clearly demonstrates how science and economics reinforce one another. Science generates breakthrough ideas, while the economy serves as the mechanism for their realization by transforming cutting-edge developments into vital and commercially successful products. As such, investing in medical science and public health creates a foundation for economic growth. This progress, in turn, spurs on the expansion of the bioeconomy, opens up new markets, and leads to new investment, thereby creating a cycle of sustainable development. In the coming years, biotechnology has the potential to become one of the key drivers of Russia’s technological sovereignty and growth in exports. This encompasses the development of new biopharmaceuticals, gene and cell therapies, advancements in personalized therapies, specifically neoantigen and recombinant vaccines, as well as CAR-T and TCR-T cell therapies, along with the development of bioinformatics platforms and big data analytics. What key discoveries in recent years have served as the foundation for creating commercially successful biotechnological products? How can we overcome the regulatory, financial, or technological obstacles that prevent biotechnological innovations from quickly reaching the market from the laboratory? Can AI and bioinformatics accelerate the development of new technologies? Which models of collaboration among universities, pharmaceutical companies, and the government are most effective for driving innovation? How is personalized therapy reshaping the structure of the pharmaceutical market and the healthcare system? What global challenges are driving investment in biotechnology?